57 results
Search Results
2. A case of cytomegalovirus esophagitis difficult to distinguish from Crohn’s disease exacerbation
3. Management of Hepatitis B in Pregnancy
4. Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B
5. Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era
6. Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B
7. Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?
8. Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies
9. Remdesivir for the Treatment of COVID-19: A Narrative Review
10. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding
11. Functions of MAP3Ks in antiviral immunity
12. Supportive care and antiviral treatments in primary herpetic gingivostomatitis: a systematic review
13. Stability and Hopf bifurcation on an immunity delayed HBV/HCV model with intra- and extra-hepatic coinfection and saturation incidence
14. Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections
15. First-line management of necrotizing herpetic retinitis by prioritizing the investigation of immune status and prognostic factors for poor visual outcomes
16. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial
17. Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants
18. 2-Deoxy-D-glucose inhibits lymphocytic choriomeningitis virus propagation by targeting glycoprotein N-glycosylation
19. TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
20. Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
21. CTLA4+CD4+CXCR5−FOXP3+ T cells associate with unfavorable outcome in patients with chronic HBV infection
22. Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial
23. A case report of long-delayed diagnosis of pseudorabies virus encephalitis with endophthalmitis: lessons from metagenomic next generation sequencing
24. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
25. Acute retinal necrosis: clinical features, management and outcomes
26. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors
27. Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study
28. Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection
29. Perspectives on current controversial issues in the management of chronic HBV infection
30. Antiviral Treatment Options for Severe Fever with Thrombocytopenia Syndrome Infections
31. Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease
32. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
33. Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels
34. Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA
35. Pregnant women and infants against the infection risk of COVID-19: a review of prenatal and postnatal symptoms, clinical diagnosis, adverse maternal and neonatal outcomes, and available treatments
36. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis
37. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
38. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
39. CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection
40. Compassionate-use pocapavir and immunoglobulin therapy for treatment of rituximab-associated enterovirus meningoencephalitis
41. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics
42. Bulevirtide als erster spezifischer Wirkstoff gegen Hepatitis-D-Virusinfektionen – Mechanismus und klinische Wirkung
43. Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy
44. Viral inactivation by light
45. Clinical characteristics, risk factors and antiviral treatments of influenza in immunosuppressed inpatients in Beijing during the 2015–2020 influenza seasons
46. CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy
47. Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis
48. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
49. Hepatitis E: vom akut-auf-chronischen Leberversagen bis zur chronischen Hepatitis E: Indikationen für eine Ribavirintherapie
50. The need for area under the curve measurements in the field of ganciclovir therapeutic drug monitoring in children: a case report
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.